PATIENTS AND METHODS
There were three separate studies: (1) a comparison between Th 1165al and salbutamol2; (2) a comparison between salmefamol13 and isoprenaline; and (3) a comparison between rimiteroll and isoprenaline ( for these patients as a log dose-response curve with the cumulative dose in puffs. Isoprenaline appears more active than salmefamol (using the paired t test P=0-02 for four puffs, and 0-05 for six puffs). Table I shows that one puff of isoprenaline contained 0-38 uM whereas one puff of salmefamol contained 015 jsM per puff, or less than one-half of one puff of isoprenaline. Figure 3 shows the results plotted with the cumulative dose expressed in micromoles, and the drugs can be seen to be equipotent. Table IV gives the individual results for the eight patients. Table I shows that one puff of rimiterol contained Hoffbrand, Hoffbrand, Hill, and Heaf (1966) found that the peak flow appeared to be a more sensitive index of changes in airways resistance after bronchodilator drugs than did measurements made with a portable bellows spirometer. However, spirometry is reproducible, simple to perform, less influenced by effort, and both the FEV, and FVC are obtained (Fairbairn, Fletcher, Tinker, and Wood, 1962) . Minette (1970) , in a study of 225 subjects, found that the reproducibility of FEV1 and FEVy.73 was superior to the reproducibility of peak flow or forced expiratory flow. He found a great stability of baseline values and the most reliable way of expressing response to bronchodilator drugs was as the absolute increment in FEV1 (AFEV1) or as the increment expressed as a percentage of the baseline (A FEV1%). Other methods of plotting results, incorporating the predicted normal value, were less satisfactory. We have therefore used the FEV1 and expressed the results as A FEV1 or A FEV1%.
Having decided on the method of measurement, there are other problems to be considered. Not only is there considerable variation between asthmatics, but Hume and Gandevia (1957) and Hume and Rhys Jones (1961) have shown that the response to a bronchodilator is related to the degree of bronchoconstriction present initially. Pain and Read (1963) showed that, even with the same baseline, responses to drugs could be different depending on whether patients were im. proving or deteriorating. These difficulties can be overcome by trials in large numbers of patients, but even then great care is needed in expressing the results (Racoveanu, Stanescu, Manicatide, and Stroescu, 1971) . Alliott et al. (1972) suggested that to keep a constant environment and to carry out the tests in as short a period as possible, studies should be done on inpatients. We agree with this, and minimized other variables by stopping all bronchodilator drugs for 10 hours before each study, using each patient as his own control, and ensuring that the baseline values were within 15% on the two study days. Furthermore, we knew before the studies that the patients were capable of responding to bronchodilator drugs, and that they had 'room' for improvement, since their FEVjs were less than 70% of the predicted values. Freedman (1971) , in a study of terbutaline, used 10 patients of whom five had an FEV1 greater than 65% of their predicted value. This makes the interpretation of results difficult, and Alliott et al. (1972) and Racoveanu et al. (1971) have attempted to overcome the problem by omitting some patients from analysis. We feel that it is better to pre-select the patients. Minette (1971) claims that average results have considerable predictive value if they are applied to large enough numbers of patients. By adhering to our criteria we are able to make direct comparisons of the two drugs being tested, and draw valid conclusions from only a few patients.
In addition our method can offer extra information. Most of the trials described above indicate comparative efficiency but not the ideal therapeutic dose. Warrell et al. (1970) , in their careful comparison of salbutamol and isoprenaline using the body plethysmograph, attempted to construct a log dose-response curve by giving increasing doses of each test drug. They had a series of four specially prepared aerosols chosen so that each dose was much larger than the dose which preceded it. This ensured that preceding doses made a relatively small contribution to the change in specific airways conductance observed after a particular dose. This produced good log doseresponse curves for each drug but involved the manufacturers in a considerable amount of work, since each aerosol has to be made up to rigid specifications. Our method is based on two assumptions: first, that once FEV1 measurements have 'levelled out' it is reasonable to give the next dose, and secondly that the time for this to occur (10 to 15 minutes) is so short that for dosage purposes the first puff can be considered still present and active when the second is given. In this way, given one, one, two, and two puffs in series, a cumulative dose has been given of one, two, four, and six puffs from the aerosol. Log dose-response curves can then be drawn and results compared within the same patient for each 'puff level', and even with as few as eight patients a paired t test can achieve statistically significant results. Furthermore, when the data are plotted graphically, a fairly accurate estimate of the relative potency of the two drugs is obtained.
In our second study, isoprenaline appeared to be significantly better than salmefamol. When the data were replotted with the dose expressed in micromoles it could readily be seen that the drugs were equipotent (Fig. 3) . For future testing we would therefore recommend that aerosols are made up in equimolar doses. Furthermore, it can be seen that four and six puffs of all the drugs had only slight advantages over two puffs, so that we would recommend two puffs as the therapeutic dose.
We are aware that 'a puff' is an inaccurate way of giving a drug, since a variable and small amount reaches the lungs (Paterson, Conolly, Davies, and Dollery, 1968) . However, this is the way in which the drug will be used therapeutically, and we feel that with patients experienced in using aerosols there is considerable consistency in technique. There may well be variations between patients but since the comparisons are made within patients this does not matter. We also have evidence that patients studied three times a day for a week show very consistent responses to a bronchodilator given by aerosol (unpublished data).
In summary, we consider that by carefully selecting patients it is possible to give a rapid and quantitative assessment of a new bronchodilator drug. This should be of considerable use to clinicians and manufacturers in the early stages of drug evaluation.
